Interview with Peter Sallstig, MD, MBA
Santen’s legacy, global products, NA product portfolio, clinical trials and more.Peter also dives into the disease state of vernal keratoconjunctivitis (VKC) and the recent US launch of Verkazia®, the first and only topical immunomodulator approved for the treatment of VKC in children and adults
As a global specialized company dedicated to ophthalmology, Santen brings a 130-year history of scientific knowledge and organizational capabilities to research, development, and commercialization of pharmaceuticals, surgical and medical devices, and OTC eye-care products. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan, and its products now reach patients in more than 60 countries. Santen provides products and services to contribute to the well-being of patients, their loved ones, and consequently to society. For more information, please visit Santen’s websites www.santenusa.com and www.santen.com (Japan headquarters).
Interview with Peter Sallstig, MD, MBA
Santen’s legacy, global products, NA product portfolio, clinical trials and more.Peter also dives into the disease state of vernal keratoconjunctivitis (VKC) and the recent US launch of Verkazia®, the first and only topical immunomodulator approved for the treatment of VKC in children and adults
